Previous Article | Next Article 
Journal of Clinical Microbiology, November 1999, p. 3514-3517, Vol. 37, No. 11
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Analysis by Multiplex PCR of the Physical Status of
Human Papillomavirus Type 16 DNA in Cervical Cancers
Mitsuo
Yoshinouchi,1
Atsushi
Hongo,1
Keichiro
Nakamura,1
Junichi
Kodama,1,*
Sachio
Itoh,2
Hiroyuki
Sakai,3 and
Takafumi
Kudo1
Department of Obstetrics and
Gynecology1 and Department of Molecular
Genetics, Institute of Cellular and Molecular
Biology,2 Okayama University Medical School,
Okayama, and Institute for Virus Research, Kyoto
University, Kyoto,3 Japan
Received 22 February 1999/Returned for modification 4 June
1999/Accepted 22 July 1999
 |
ABSTRACT |
Integration of human papillomavirus (HPV) DNA occurs early in
cancer development and is an important event in malignant
transformation of cervical cancer. Integration of HPVs preferentially
disrupts or deletes the E2 open reading frame, which results in the
loss of its expression. The preferential disruption of the E2 gene causes the absence of the E2 gene sequences in the PCR product following integration. Twenty-two carcinomas positive for HPV type 16 (HPV-16) DNA were first tested for the disruption of the E2 gene by
PCR. A specific fragment of the E2 gene was not amplified in 10 cases,
suggesting integration of HPV DNA into the host genome. Next, multiplex
PCR for the HPV E2 and E6 genes was carried out in the remaining 12 cases. Copy numbers of both genes should be equivalent in episomal
forms, while the E2 gene copy number will be smaller than that for E6
following the preferential disruption of the E2 gene in concominant
forms. Although relative ratios of HPV E2 to E6 PCR products (E2/E6
ratios) ranged from 1.40 to 2.34 in 10 of 12 cases, multiplex PCR
products from 2 cases displayed extremely low ratios of 0.69 and 0.61. Southern blot hybridization with an HPV-16 probe revealed that only in
these two cases was both episomal and integrated HPV DNA being carried
simultaneously. Thus, multiplex PCR for the E2 and E6 genes of HPV-16
DNA following PCR for the E2 gene can distinguish the pure episomal
form from a mixed form of episomal and integrated HPV DNA. Clinical
application of this technique will help researchers to understand the
implication of the integration of HPV DNA for cervical carcinogenesis
and cervical cancer progression.
 |
INTRODUCTION |
A strong association between
specific human papillomavirus (HPV) types and anogenital cancer has
been well established. Certain types of HPV, including types 16, 18, 31, 33, 35, 45, 52, 56, and 58, play a pivotal role in the
carcinogenesis of cervical cancer (33). In fact, the HPV
viral DNA is identified in at least 90% of cervical carcinomas by PCR
(2, 16, 30). The viral DNA is integrated into the cellular
genome in cell lines derived from cervical carcinomas (3, 13, 27,
32) and in the majority of malignant tumors (6, 28).
In contrast, integration of HPV DNA, regardless of type, occurs
infrequently in preneoplastic-lesion, cervical intraepithelial
neoplasia (CIN). Thus, integration has been proposed as an activation
mechanism for progression from preinvasive lesions to cervical cancers
(2, 6, 28).
It is known that integration usually disrupts or deletes either the E1
or E2 open reading frame (ORF), which results in the loss of expression
of the corresponding gene products. Disruption of the E1 and E2 genes
also leads to overexpression of the E6 and E7 oncoproteins (11,
15), since the E2 gene product can repress activities from the
HPV promoters that direct the expression of the E6 and E7 genes
(1, 21, 26). The preferential disruption of the E2 gene will
cause the absence of the E2 gene sequences in the PCR product following
integration. Thus, accurate detection of the integration of HPV DNA was
achieved by using a simple PCR technique to amplify the E2 gene
(8, 19). This rapid method, however, has limitations for
distinguishing pure episomal forms of HPV DNA from mixed forms of
episomal and integrated HPV DNA. Here, we report an accurate method of
multiplex PCR for E2 and E6 to differentiate all physical types of HPV
type 16 (HPV-16) DNA.
 |
MATERIALS AND METHODS |
Tissue specimens and DNA extraction.
Primary lesions were
screened for the presence of HPV DNA as described previously
(17). Twenty-two invasive carcinoma specimens positive for
HPV-16 DNA were included in the present study. Specimens were obtained
at the time of admission for surgery at the Department of Obstetrics
and Gynecology, Okayama University Medical School Hospital, Okayama,
Japan. DNA was extracted from tissue specimens and CaSki cell lines
(20) by a routine procedure of proteinase K digestion and
phenol extraction.
PCRs for E2 and a mixture of E2 and E6.
For detection of
integration, the E2 ORF of the HPV-16 genome between nucleotides 2810 and 3836 was amplified according to the PCR conditions described by
Park et al. (19). Next, multiplex PCR for the HPV E2 and E6
genes, both of which were in the same reaction tube, was performed. The
primers for each sequence were 5'-CTTGGGCACCGAAGAAACAC-3'
(nucleotides 3438 to 3457) and 5'-TTGGTCACGTTGCCATTCAC-3' (nucleotides 3770 to 3789) for the E2 gene and
5'-AAGGGCGTAACCGAAATCGGT-3' (nucleotides 26 to 46) and
5'-CATATACCTCACGTCGCAG-3' (nucleotides 215 to 233) for the
E6 gene. These primers yielded 352- and 208-bp fragments for the E2 and
E6 sequences, respectively. The conditions for multiplex PCR were the
same as those previously described for the c-erbB-2 gene and
the mdm-2 genes (23, 24). All
oligodeoxynucleotides were synthesized with a model 394 DNA synthesizer
(Applied Biosystems, Foster City, Calif.). PCR products were
electrophoresed on a 2% agarose gel and stained with ethidium bromide.
The UV-illuminated gels were photographed with Polaroid negatives (type
665), quantitated with an image scanner (GT8000; Epson, Suwa, Japan),
and analyzed with Intelligent Quantifier software (Bio Image, Ann
Arbor, Mich.). The relative ratio of HPV E2 to E6 PCR products (E2/E6
ratio) was calculated. In order to verify the constancy of the E2/E6 ratio, the amount of template DNA (0.5 to 20 pg) or the number of
amplification cycles (20 to 35) was altered by using HPV-16 plasmid DNA
as the template DNA. E2/E6 ratios in this preliminary experiment always
exceeded 1.28 (data not shown).
Southern blot hybridization.
Ten micrograms of genomic DNA
was digested with BamHI or PstI (New England
Biolabs, Inc., Beverly, Mass.), electrophoresed in 1% agarose gels,
and transferred onto nylon membranes (Hybond N; Amersham, Little
Chalfont, Buckinghamshire, United Kingdom) by Southern blot procedures
(25). BamHI has one cleavage site for HPV-16 DNA,
while PstI is a multicut enzyme yielding the characteristic cleavage pattern. The membranes were sequentially hybridized with a
32P-labelled HPV-16 probe (11).
 |
RESULTS |
E2 PCR and multiplex PCR for E2 and E6.
All invasive cervical
cancer specimens were screened for the presence of HPV-16 DNA by nested
PCR for the E6 gene (data not shown). Twenty-two carcinomas positive
for HPV-16 DNA were then tested for the disruption of the HPV-16 E2
gene by PCR for E2. The specific fragment of the E2 gene (described
above) was not amplified in 10 cases, suggesting integration of HPV DNA
into the host genome in these cases. In contrast, the expected fragment of 1,027 bp was abundantly amplified in the remaining 12 cases (Fig.
1). In these cases, therefore, it was
postulated that HPV DNA was present in episomal form without any
disruption of the E2 gene. It was possible, however, that HPV DNA in
these cancers exists in pure episomal form or in mixed episomal and
integration forms.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 1.
PCR for the E2 ORF of HPV-16 DNA. Cervical carcinomas
positive for HPV-16 DNA were examined for the disruption of the HPV-16
E2 gene by PCR. No amplification of a specific fragment of the E2 gene
(1,027 bp) suggested the integration of HPV DNA into the host genome
(lanes 1, 4, and 6). When the E2 gene was abundantly amplified, it was
postulated that HPV DNA is present in episomal form without any
disruption of the E2 gene (lanes 2, 3, 5, and 7).
|
|
Multiplex PCR for the HPV E2 and E6 genes was carried out in these 12 cases. Specific fragments of the E2 and E6 genes were successfully
coamplified in all cases (Fig. 2).
Although E2/E6 ratios ranged from 1.40 to 2.34 in 10 of 12 cases,
multiplex PCR products from 2 cases displayed extremely low ratios of
0.69 and 0.61.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2.
Multiplex PCR for the E2 and E6 genes of HPV-16 DNA.
Cervical carcinomas with intact E2 genes were subjected to multiplex
PCR for the E2 and E6 genes. Specific fragments of the E2 (352 bp) and
E6 genes (208 bp) were successfully coamplified in all cases. The E2/E6
ratio was obtained by densitometry. E2/E6 ratios for two cases were
extremely low (0.69 and 0.61) compared to others (lanes 3 and 7).
|
|
Southern blot hybridization to analyze the physical status of
HPV-16 DNA.
Southern blot hybridization was carried out with an
HPV-16 DNA probe for confident detection of the physical status of
HPV-16 DNA in these cervical carcinomas. Ten micrograms of tumorous DNA was first digested with single-cut enzyme BamHI and
hybridized with an HPV-16 DNA probe. A single 7.9-kb band is supposed
to appear when HPV DNA is episomal, and an off-sized fragment will appear when HPV DNA is integrated into the host genome. Figure 3 is a representative autoradiograph for
five tumors. Lane 1 shows the single 7.9-kb band that was totally
converted from the episomal DNA to a linear form upon BamHI
digestion. Lanes 2 and 3 exhibit the presence of a couple of off-sized
fragments and the absence of any 7.9-kb band, indicating that these are
purely integrated HPV DNAs. Lanes 4 and 5 show the single 7.9-kb band
as well as off-sized fragments smaller than 7.9 kb, suggesting that HPV
DNA exists in mixed episomal and integration forms in these cancers. These lanes represent two cancers from which multiplex PCR
products displayed E2/E6 ratios much lower than those for the PCR
products in the other lanes.

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 3.
Southern blot hybridization to analyze physical status
of HPV-16 DNA. Ten micrograms of tumorous DNA was digested with
single-cut enzyme BamHI and hybridized with an HPV-16 DNA
probe. A single 7.9-kb band is shown when HPV DNA is episomal (lane 1).
Off-sized fragments (arrowheads) appear when HPV DNA is
integrated into the host genome (lanes 2 and 3). Lanes 4 and 5 show the
single 7.9-kb band as well as off-sized fragments smaller than 7.9 kb,
suggesting that HPV DNA exists as mixed episomal and integration forms
in these cancers. Molecular size standards, in kilobases, are shown to
the left.
|
|
For confirmation of the simultaneous existence of episomal and
integrated HPV DNA, genomic DNAs from these two cases were next
digested with PstI, a multicut enzyme, to yield the
authentic cleavage pattern. Genomic DNAs that exhibited the purely
episomal HPV DNA were also digested with PstI and served as
controls (Fig. 4). These controls show
characteristic BamHI and PstI cleavage patterns
(lanes 1 and 2). In contrast, the two cancers with extremely low E2/E6
ratios showed additional off-sized fragments along with authentic
PstI fragments (lanes 3 and 4). This confirmed that HPV DNA
exists in mixed episomal and integration forms in these cancers.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 4.
Southern blot hybridization following digestion with
single-cut enzyme BamHI (B) and multicut enzyme
PstI (P). PstI digestion is supposed to yield the
authentic cleavage pattern, i.e., 2.8, 1.9, 1.6, and 1.0 kb (indicated
at the right) and 0.5 kb (invisible in this panel). DNAs representing
purely episomal HPV DNA were loaded in lanes 1 and 2. The two
specimens with extremely low E2/E6 ratios showed additional off-sized
fragments (arrowheads) along with authentic PstI fragments
(lanes 3 and 4).
|
|
 |
DISCUSSION |
The viral genomes are exclusively maintained as episomes in benign
lesions induced by HPVs such as HPV-6 and -11 (10, 17). Only
episomal HPV DNA is detected in CIN type I (CIN-I), and integrated sequences are rarely found in CIN-II and -III (6, 8). In contrast, the viral DNA is usually integrated into the cellular genome
in cell lines derived from cervical carcinomas (3, 13, 27,
32) and in the majority of malignant tumors (6, 28). Thus, integration occurs early in cancer development and is an important event in malignant transformation (2, 6, 28). Several studies have also demonstrated the stable persistence of
integrated HPV DNA in the invasive tumor cells or the presence of HPV
DNA sequences in cancer cells that exist within metastatic lymph nodes
(5, 7, 12, 18, 31). This phenomenon made it possible to
predict the unexpected recurrence of cervical cancer in patients with
histologically negative nodes by a sensitive nested PCR for HPV DNA
(17).
Thus, accurate detection of the physical status of HPV DNA is very
important for a better understanding of the mechanisms of cervical
carcinogenesis and of cervical cancer progression and metastasis. To
analyze the physical status of HPV, a number of Southern blots and,
sometimes, two-dimensional gel electrophoresis are essential. These
procedures require large quantities of high-molecular-weight DNA, which
is an obstacle when working with tiny intraepithelial lesions.
It is widely known that the transforming properties of the E6 and E7
oncoproteins are due, in part, to their capacity to bind to the p53 and
the retinoblastoma tumor suppressor proteins and to inactivate the
functions of their putative checkpoint controls (29).
Integration of the viral genome into the human chromosome in the cancer
cells usually disrupts or deletes the E2 ORF, which results in the loss
of expression of the E2 gene, but high levels of E6 and E7 expression
are maintained (11, 15). The E2 gene encodes a site-specific
DNA-binding protein that is involved in the regulation of the HPV
promoter that directs E6 and E7 expression (1, 21, 26). The
reintroduction of the E2 gene into cervical carcinoma cell lines
thereby leads to the inhibition of cell proliferation (10,
14).
The preferential disruption of the E2 genes will cause an absence of
the E2 gene sequences in the PCR product following integration. Accurate detection of the integration of HPV DNA was achieved by
a PCR technique to amplify the E2 gene (8, 19). First, we explored the presence of the E2 gene by amplifying the E2 ORF. A
specific fragment of the E2 gene was not amplified in 10 of 22 cases
(45.5%) with HPV-16 DNA. These cases involved the integrated form of
HPV DNA. The frequency of viral integration that we found is slightly
lower than those from preceding studies using the same method (8,
19). Since PCR for E2 and conventional Southern blot analysis in
these previous studies were in complete concordance concerning the
detection of the integration of HPV DNA, we presume such a small
difference is due to epidemiological differences among the population
studied. However, to rule out the possibility of integration outside
the E2 ORF, including the E1 ORF, additional sets of primers from these
regions may have to be used for further confirmation.
In the remaining 12 cases with an intact E2 gene, there are two
possibilities: a pure episomal form or the concomitant presence of
episomal and integration forms. We then tried multiplex PCR for the E2
and E6 genes to differentiate between these possibilities. The copy
numbers of both genes should be equivalent in episomal forms, while the
E2 gene copy number will be smaller than that for E6 following the
preferential disruption of the E2 gene in concomitant forms. As
expected, in a preliminary experiment with HPV-16 plasmid DNA, E2/E6
ratios were independent of the amount of template DNA and the number of
amplification cycles. Next, we applied this technique to a survey of
the differences in the copy numbers of both genes in 12 cases with an
intact E2 gene. Multiplex PCR products from two cases displayed
extremely low ratios of 0.69 and 0.61 compared to those for the other
cases (1.40 to 2.34) (Fig. 2). These two cases might involve mixed
episomal and integration forms.
In order to verify the simultaneous existence of episomal and
integration forms of HPV DNA, conventional Southern hybridization was carried out with an HPV-16 DNA probe. Digestion of genomic DNA with
BamHI or PstI is generally used for the accurate
detection of the physical status of HPV-16 DNA (22).
BamHI has one cleavage site for HPV-16 DNA, while
PstI is a multicut enzyme yielding the authentic cleavage
pattern. Control DNAs representing the purely episomal HPV DNA showed
the linearized single 7.9-kb band upon BamHI digestion (Fig.
3, lane 1, and Fig. 4, lanes 1 and 2). In contrast, integrated HPV DNA
exhibited the presence of a couple of off-sized fragments and the
absence of any 7.9-kb band (Fig. 3, lanes 2 and 3). When DNAs from two
cases with extremely low E2/E6 ratios were digested with
BamHI, the single 7.9-kb band and off-sized fragments
smaller than 7.9 kb were observed in the Southern blots, suggesting the
simultaneous existence of episomes and integration forms of HPV DNA in
these cancers (Fig. 3, lanes 4 and 5). To further confirm these
results, DNAs were digested with PstI. Additional off-sized
fragments along with PstI-specific restriction fragments
were clearly observed in the Southern blots (Fig. 4, lanes 3 and 4).
These two cancers are undoubtedly carrying both episomal and
integrated HPV forms.
PCR amplifying the E2 ORF is a useful complement to prove the
integrated form of HPV DNA (8). Reverse transcription-PCR for the E2 gene seems to be more sensitive than PCR for DNA
(19). These methods, nevertheless, have limitations
for distinguishing the pure episomal form of HPV DNA from mixed forms
of episomal and integrated HPV DNA, because the E2 sequence is
retained on the episomes in both cases. Our multiplex PCR for E2 and E6
is expected to solve this problem. It is possible that this tool cannot
determine the physical status of HPV DNA accurately when concomitant
episomal forms with relatively small amounts of HPV DNA exist due to
limitations in the sensitivity for quantitation of the PCR products.
HPV multimers carrying some deletions or duplications have been also
reported (4, 9). Although a range of E2/E6 ratios for
determination of the purely episomal forms will be required, we could
not determine a cutoff value from the present study. It is widely
believed that integrated sequences are rarely found in CIN-II and -III,
but it is likely that the simultaneous presence of episomal and
integrated forms in CINs and invasive carcinomas is more
frequent. These lesions are generally small, and a sufficient
amount of DNAs is not always available. A PCR-based analysis of the
physical status of HPV DNA is applicable to small amounts of DNA
purified from tiny lesions, formalin-fixed paraffin-embedded tissues,
or cervical cytological specimens. Clinical application of this
technique will help researchers to understand the implications of the
integration of HPV for cervical carcinogenesis and the progression of
cervical cancer.
Similar investigations for other types of HPV DNA will be easy to
establish. In fact, we have found PCR primers that can coamplify the E2
and E6 genes of HPV-18 with satisfactory sensitivity and efficacy.
Unfortunately, all carcinomas revealed exclusively integrated HPV
except for one, which presented both episomal and integration forms
(data not shown).
In conclusion, multiplex PCR for the E2 and E6 genes of HPV-16 DNA
following PCR for the E2 gene can help researchers to analyze the
physical status of HPV DNA.
 |
ACKNOWLEDGMENTS |
This work was supported in part by grants-in-aid 09671684 and
09771277 from the Ministry of Education, Sport, Science and Culture, Japan.
We thank A. Dusso, Renal Division, Washington University School of
Medicine, for assistance in the preparation of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Obstetrics and Gynecology, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700, Japan. Phone: (81) 86 235 7320. Fax: (81) 86 225 9570. E-mail: kodama{at}cc.okayama-u.ac.jp.
 |
REFERENCES |
| 1.
|
Bernard, B. A.,
C. Bailly,
M.-C. Lenoir,
M. Darmon,
F. Thierry, and M. Yaniv.
1989.
The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV 18 regulatory region in human keratinocytes.
J. Virol.
63:4317-4324[Abstract/Free Full Text].
|
| 2.
|
Bosch, F. X.,
M. M. Manos,
N. Munoz,
M. Sherman,
A. M. Jansen,
J. Peto,
M. H. Schiffman,
V. Moreno,
R. Kurman, and K. V. Shah.
1995.
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.
J. Natl. Cancer Inst.
87:796-802[Abstract/Free Full Text].
|
| 3.
|
Boshart, M.,
L. Gissmann,
H. Ikenberg,
A. Kleinheinz,
W. Scheurlen, and H. zur Hausen.
1984.
A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer.
EMBO J.
3:1151-1157[Medline].
|
| 4.
|
Choo, K.,
W. Cheung,
L. Liew,
H. Lee, and S. Han.
1989.
Presence of catenated human papillomavirus type 16 episomes in a cervical carcinoma cell line.
J. Virol.
63:782-789[Abstract/Free Full Text].
|
| 5.
|
Claas, E. C. J.,
W. J. G. Melchers,
H. C. van der Linden,
J. Lindeman, and W. G. V. Quint.
1989.
Human papillomavirus detection in paraffin-embedded cervical carcinomas and metastases of the carcinomas by the polymerase chain reaction.
Am. J. Pathol.
135:703-709[Abstract].
|
| 6.
|
Cullen, A. P.,
R. Reid,
M. Campion, and A. T. Lorincz.
1991.
Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasms.
J. Virol.
65:606-612[Abstract/Free Full Text].
|
| 7.
|
Czeglédy, J.,
R. Póka,
G. Veress, and L. Gergely.
1992.
Amplification of human papillomavirus type 16 transforming genes from cervical cancer biopsies and lymph nodes of Hungarian patients.
J. Clin. Microbiol.
30:233-236[Abstract/Free Full Text].
|
| 8.
|
Das, B. C.,
J. K. Sharma,
V. Gopalakrishna, and U. K. Luthra.
1992.
Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions.
J. Gen. Virol.
73:2327-2336[Abstract/Free Full Text].
|
| 9.
|
Di Luca, D.,
P. Monini,
A. Rotola,
A. Saviolli, and E. Cassai.
1989.
Episomal HPV 16 DNA isolated from a cervical carcinoma presents a partial duplication of the early region.
Virus Res.
14:49-56[Medline].
|
| 10.
|
Dowhanick, J. J.,
A. A. McBride, and P. M. Howley.
1995.
Suppression of cellular proliferation by the papillomavirus E2 protein.
J. Virol.
69:7791-7799[Abstract].
|
| 11.
|
Dürst, M.,
A. Kleinheinz,
M. Hotz, and L. Gissman.
1985.
The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumors.
J. Gen. Virol.
66:1515-1522[Abstract/Free Full Text].
|
| 12.
|
Fuchs, P. G.,
F. Girardi, and H. Pfister.
1989.
Human papillomavirus 16 DNA in cervical cancers and in lymph nodes of cervical cancer patients: a diagnostic marker for early metastases?
Int. J. Cancer
43:41-44[Medline].
|
| 13.
|
Howley, P. M.
1985.
Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.
Am. J. Pathol.
119:361-366[Abstract].
|
| 14.
|
Hwang, E. S.,
D. J. Riese II,
J. Settleman,
L. A. Nilson,
J. Honig,
S. Flynn, and D. DiMaio.
1993.
Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene.
J. Virol.
67:3720-3729[Abstract/Free Full Text].
|
| 15.
|
Jeon, S., and P. F. Lambert.
1995.
Integration of HPV-16 DNA into the human genome leads to increased stability of E6/E7 mRNAs: implications for cervical carcinogenesis.
Proc. Natl. Acad. Sci. USA
92:1654-1658[Abstract/Free Full Text].
|
| 16.
|
Karlsen, F.,
M. Kalantari,
A. Jenkins,
E. Pettersen,
G. Kristensen,
R. Holm,
B. Johansson, and B. Hagmar.
1996.
Use of multiple PCR primer sets for optimal detection of human papillomavirus.
J. Clin. Microbiol.
34:2095-2100[Abstract].
|
| 17.
|
Kobayashi, Y.,
M. Yoshinouchi,
G. Tianqi,
K. Nakamura,
A. Hongo,
S. Kamimura,
Y. Mizutani,
J. Kodama,
Y. Miyagi, and T. Kudo.
1998.
Presence of human papilloma virus DNA in pelvic lymph nodes can predict unexpected recurrence of cervical cancer in patients with histologically negative lymph nodes.
Clin. Cancer Res.
4:979-983[Abstract].
|
| 18.
|
Lewandowski, G.,
G. Delgado,
R. W. Holloway,
M. Farrell,
B. Jenson, and W. D. Lancaster.
1990.
The use of in situ hybridization to show human papillomavirus deoxyribonucleic acid in metastatic cancer cells within lymph nodes.
Am. J. Obstet. Gynecol.
163:1333-1337[Medline].
|
| 19.
|
Park, J. S.,
E. S. Hwang,
S. N. Park,
H. K. Ahn,
S. J. Um,
C. J. Kim, and S. J. Kim.
1997.
Physical status and expression of HPV genes in cervical cancers.
Gynecol. Oncol.
65:121-129[Medline].
|
| 20.
|
Pattilo, R. A.,
R. O. Hussa,
M. T. Story,
A. C. F. Ruckert,
M. R. Shalaby, and R. F. Mattingly.
1977.
Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line.
Science
196:1456-1458[Abstract/Free Full Text].
|
| 21.
|
Romanczuk, H.,
F. Thierry, and P. M. Howley.
1990.
Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters.
J. Virol.
64:2849-2859[Abstract/Free Full Text].
|
| 22.
|
Seedorf, K.,
G. Krämmer,
M. Dürst,
S. Suhai, and W. G. Röwekamp.
1985.
Human papillomavirus-type-16 DNA sequence.
Virology
145:181-185[Medline].
|
| 23.
|
Seki, A.,
J. Kodama,
Y. Miyagi,
S. Kamimura,
M. Yoshinouchi, and T. Kudo.
1997.
Amplification of the mdm-2 gene and P53 abnormalities in uterine sarcomas.
Int. J. Cancer.
73:33-37[Medline].
|
| 24.
|
Seki, A.,
K. Nakamura,
J. Kodama,
Y. Miyagi,
M. Yoshinouchi, and T. Kudo.
1998.
A close correlation between c-erbB-2 gene amplification and local progression in endometrial adenocarcinoma.
Eur. J. Gynaecol. Oncol.
19:90-92[Medline].
|
| 25.
|
Southern, E. M.
1975.
Detection of specific sequences among DNA fragments separated by gel electrophoresis.
J. Mol. Biol.
98:503-517[Medline].
|
| 26.
|
Thierry, F., and P. M. Howley.
1991.
Functional analysis of E2 mediated repression of the HPV 18 P105 promotor.
New Biol.
3:90-100[Medline].
|
| 27.
|
Tsunokawa, Y.,
N. Takebe,
S. Nozawa,
T. Kasamatsu,
L. Gissmann,
H. zur Hausen,
M. Terada, and T. Sugimura.
1986.
Presence of human papillomavirus type-16 and type-18 DNA sequences and their expression in cervical cancers and cell lines from Japanese patients.
Int. J. Cancer
37:499-503[Medline].
|
| 28.
|
Vernon, S. D.,
E. R. Unger,
D. L. Miller,
D. R. Lee, and W. C. Reeves.
1997.
Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer.
Int. J. Cancer
74:50-56[Medline].
|
| 29.
|
Vousden, K.
1993.
Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes.
FASEB J.
7:872-879[Abstract].
|
| 30.
|
Walboomers, J. M., and C. J. Meijer.
1997.
Do HPV-negative cervical carcinomas exist?
J. Pathol.
181:253-254[Medline].
|
| 31.
|
Walboomers, J. M. M.,
H. E. Fokke,
M. Polak,
H. Volkers,
H. J. Houthoff,
J. Barents,
J. van der Noordaa, and J. ter Schegget.
1987.
In situ localization of human papilloma virus type 16 DNA in a metastasis of an endocervical adenocarcinoma.
Intervirology
27:81-85[Medline].
|
| 32.
|
Yee, C.,
I. Krishnan-Hewlett,
C. C. Baker,
R. Schlegel, and P. M. Howley.
1985.
Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.
Am. J. Pathol.
119:361-366.
|
| 33.
|
zur Hausen, H.
1996.
Papillomavirus infections a major cause of human cancers.
Biochim. Biophys. Acta
1288:55-78.
|
Journal of Clinical Microbiology, November 1999, p. 3514-3517, Vol. 37, No. 11
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Arias-Pulido, H., Peyton, C. L., Joste, N. E., Vargas, H., Wheeler, C. M.
(2006). Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer.. J. Clin. Microbiol.
44: 1755-1762
[Abstract]
[Full Text]
-
Cid-Arregui, A., Juarez, V., Hausen, H. z.
(2003). A Synthetic E7 Gene of Human Papillomavirus Type 16 That Yields Enhanced Expression of the Protein in Mammalian Cells and Is Useful for DNA Immunization Studies. J. Virol.
77: 4928-4937
[Abstract]
[Full Text]
-
Lukaszuk, K., Liss, J., Wozniak, I., Emerich, J., Wojcikowski, C.
(2003). Human Papillomavirus Type 16 Status in Cervical Carcinoma Cell DNA Assayed by Multiplex PCR. J. Clin. Microbiol.
41: 608-612
[Abstract]
[Full Text]
-
Burd, E. M.
(2003). Human Papillomavirus and Cervical Cancer. Clin. Microbiol. Rev.
16: 1-17
[Abstract]
[Full Text]
-
Nagao, S., Yoshinouchi, M., Miyagi, Y., Hongo, A., Kodama, J., Itoh, S., Kudo, T.
(2002). Rapid and Sensitive Detection of Physical Status of Human Papillomavirus Type 16 DNA by Quantitative Real-Time PCR. J. Clin. Microbiol.
40: 863-867
[Abstract]
[Full Text]